This is a single-center observational study evaluating the potential value of NfL as a biomarker for diagnosis, detection of disease onset, monitoring of disease progression, and treatment response in asymptomatic carriers of TTR variants and symptomatic hATTR amyloidosis patients with polyneuropathy.
Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.
Alnylam Pharmaceuticals (ALNY) is the sponsoring company for this trial. BiotechSign currently grades this company C (53/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.